<?xml version='1.0' encoding='utf-8'?>
<document id="19015329"><sentence text="Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir."><entity charOffset="31-43" id="DDI-PubMed.19015329.s1.e0" text="ketoconazole" /><entity charOffset="48-57" id="DDI-PubMed.19015329.s1.e1" text="ritonavir" /><entity charOffset="66-76" id="DDI-PubMed.19015329.s1.e2" text="saquinavir" /><pair ddi="false" e1="DDI-PubMed.19015329.s1.e0" e2="DDI-PubMed.19015329.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19015329.s1.e0" e2="DDI-PubMed.19015329.s1.e1" /><pair ddi="false" e1="DDI-PubMed.19015329.s1.e0" e2="DDI-PubMed.19015329.s1.e2" /><pair ddi="false" e1="DDI-PubMed.19015329.s1.e1" e2="DDI-PubMed.19015329.s1.e1" /><pair ddi="false" e1="DDI-PubMed.19015329.s1.e1" e2="DDI-PubMed.19015329.s1.e2" /></sentence><sentence text="Saquinavir, a potent human immunodeficiency virus protease inhibitor, is extensively metabolized by CYP3A4"><entity charOffset="0-10" id="DDI-PubMed.19015329.s2.e0" text="Saquinavir" /></sentence><sentence text=" Saquinavir is coadministered with ritonavir, a strong CYP3A4 inhibitor, to boost its exposure"><entity charOffset="1-11" id="DDI-PubMed.19015329.s3.e0" text="Saquinavir" /><entity charOffset="35-44" id="DDI-PubMed.19015329.s3.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.19015329.s3.e0" e2="DDI-PubMed.19015329.s3.e0" /><pair ddi="false" e1="DDI-PubMed.19015329.s3.e0" e2="DDI-PubMed.19015329.s3.e1" /></sentence><sentence text=" Ketoconazole is a potent CYP3A inhibitor"><entity charOffset="1-13" id="DDI-PubMed.19015329.s4.e0" text="Ketoconazole" /></sentence><sentence text=" The objectives of this study were to investigate the effect of ketoconazole on the pharmacokinetics of saquinavir/ritonavir and vice versa using the approved dosage regimens of saquinavir/ritonavir at 1,000/100 mg twice daily and ketoconazole at 200 mg once daily"><entity charOffset="64-76" id="DDI-PubMed.19015329.s5.e0" text="ketoconazole" /><entity charOffset="104-114" id="DDI-PubMed.19015329.s5.e1" text="saquinavir" /><entity charOffset="115-124" id="DDI-PubMed.19015329.s5.e2" text="ritonavir" /><entity charOffset="178-188" id="DDI-PubMed.19015329.s5.e3" text="saquinavir" /><entity charOffset="189-198" id="DDI-PubMed.19015329.s5.e4" text="ritonavir" /><entity charOffset="231-243" id="DDI-PubMed.19015329.s5.e5" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.19015329.s5.e0" e2="DDI-PubMed.19015329.s5.e0" /><pair ddi="false" e1="DDI-PubMed.19015329.s5.e0" e2="DDI-PubMed.19015329.s5.e1" /><pair ddi="false" e1="DDI-PubMed.19015329.s5.e0" e2="DDI-PubMed.19015329.s5.e2" /><pair ddi="false" e1="DDI-PubMed.19015329.s5.e0" e2="DDI-PubMed.19015329.s5.e3" /><pair ddi="false" e1="DDI-PubMed.19015329.s5.e0" e2="DDI-PubMed.19015329.s5.e4" /><pair ddi="false" e1="DDI-PubMed.19015329.s5.e0" e2="DDI-PubMed.19015329.s5.e5" /><pair ddi="false" e1="DDI-PubMed.19015329.s5.e1" e2="DDI-PubMed.19015329.s5.e1" /><pair ddi="false" e1="DDI-PubMed.19015329.s5.e1" e2="DDI-PubMed.19015329.s5.e2" /><pair ddi="false" e1="DDI-PubMed.19015329.s5.e1" e2="DDI-PubMed.19015329.s5.e3" /><pair ddi="false" e1="DDI-PubMed.19015329.s5.e1" e2="DDI-PubMed.19015329.s5.e4" /><pair ddi="false" e1="DDI-PubMed.19015329.s5.e1" e2="DDI-PubMed.19015329.s5.e5" /><pair ddi="false" e1="DDI-PubMed.19015329.s5.e2" e2="DDI-PubMed.19015329.s5.e2" /><pair ddi="false" e1="DDI-PubMed.19015329.s5.e2" e2="DDI-PubMed.19015329.s5.e3" /><pair ddi="false" e1="DDI-PubMed.19015329.s5.e2" e2="DDI-PubMed.19015329.s5.e4" /><pair ddi="false" e1="DDI-PubMed.19015329.s5.e2" e2="DDI-PubMed.19015329.s5.e5" /><pair ddi="false" e1="DDI-PubMed.19015329.s5.e3" e2="DDI-PubMed.19015329.s5.e3" /><pair ddi="false" e1="DDI-PubMed.19015329.s5.e3" e2="DDI-PubMed.19015329.s5.e4" /><pair ddi="false" e1="DDI-PubMed.19015329.s5.e3" e2="DDI-PubMed.19015329.s5.e5" /><pair ddi="false" e1="DDI-PubMed.19015329.s5.e4" e2="DDI-PubMed.19015329.s5.e4" /><pair ddi="false" e1="DDI-PubMed.19015329.s5.e4" e2="DDI-PubMed.19015329.s5.e5" /></sentence><sentence text=" This was an open-label, randomized two-arm, one-sequence, two-period crossover study in healthy subjects" /><sentence text=" In study arm 1, 20 subjects received saquinavir/ritonavir treatment alone for 14 days, followed in combination with ketoconazole treatment for 14 days"><entity charOffset="38-48" id="DDI-PubMed.19015329.s7.e0" text="saquinavir" /><entity charOffset="49-58" id="DDI-PubMed.19015329.s7.e1" text="ritonavir" /><entity charOffset="117-129" id="DDI-PubMed.19015329.s7.e2" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.19015329.s7.e0" e2="DDI-PubMed.19015329.s7.e0" /><pair ddi="false" e1="DDI-PubMed.19015329.s7.e0" e2="DDI-PubMed.19015329.s7.e1" /><pair ddi="false" e1="DDI-PubMed.19015329.s7.e0" e2="DDI-PubMed.19015329.s7.e2" /><pair ddi="false" e1="DDI-PubMed.19015329.s7.e1" e2="DDI-PubMed.19015329.s7.e1" /><pair ddi="false" e1="DDI-PubMed.19015329.s7.e1" e2="DDI-PubMed.19015329.s7.e2" /></sentence><sentence text=" In arm 2, 12 subjects received ketoconazole treatment for 6 days, followed in combination with saquinavir/ritonavir treatment for 14 days"><entity charOffset="32-44" id="DDI-PubMed.19015329.s8.e0" text="ketoconazole" /><entity charOffset="96-106" id="DDI-PubMed.19015329.s8.e1" text="saquinavir" /><entity charOffset="107-116" id="DDI-PubMed.19015329.s8.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.19015329.s8.e0" e2="DDI-PubMed.19015329.s8.e0" /><pair ddi="false" e1="DDI-PubMed.19015329.s8.e0" e2="DDI-PubMed.19015329.s8.e1" /><pair ddi="false" e1="DDI-PubMed.19015329.s8.e0" e2="DDI-PubMed.19015329.s8.e2" /><pair ddi="false" e1="DDI-PubMed.19015329.s8.e1" e2="DDI-PubMed.19015329.s8.e1" /><pair ddi="false" e1="DDI-PubMed.19015329.s8.e1" e2="DDI-PubMed.19015329.s8.e2" /></sentence><sentence text=" The pharmacokinetics were assessed on the last day of each treatment (days 14 and 28 in arm 1 and days 6 and 20 in arm 2)" /><sentence text=" The exposures C(max) and the area under the concentration-time curve from 0 to 12 h (AUC(0-12)) of saquinavir and ritonavir with or without ketoconazole were not substantially altered after 2 weeks of concomitant dosing with ketoconazole"><entity charOffset="100-110" id="DDI-PubMed.19015329.s10.e0" text="saquinavir" /><entity charOffset="115-124" id="DDI-PubMed.19015329.s10.e1" text="ritonavir" /><entity charOffset="141-153" id="DDI-PubMed.19015329.s10.e2" text="ketoconazole" /><entity charOffset="226-238" id="DDI-PubMed.19015329.s10.e3" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.19015329.s10.e0" e2="DDI-PubMed.19015329.s10.e0" /><pair ddi="false" e1="DDI-PubMed.19015329.s10.e0" e2="DDI-PubMed.19015329.s10.e1" /><pair ddi="false" e1="DDI-PubMed.19015329.s10.e0" e2="DDI-PubMed.19015329.s10.e2" /><pair ddi="false" e1="DDI-PubMed.19015329.s10.e0" e2="DDI-PubMed.19015329.s10.e3" /><pair ddi="false" e1="DDI-PubMed.19015329.s10.e1" e2="DDI-PubMed.19015329.s10.e1" /><pair ddi="false" e1="DDI-PubMed.19015329.s10.e1" e2="DDI-PubMed.19015329.s10.e2" /><pair ddi="false" e1="DDI-PubMed.19015329.s10.e1" e2="DDI-PubMed.19015329.s10.e3" /><pair ddi="false" e1="DDI-PubMed.19015329.s10.e2" e2="DDI-PubMed.19015329.s10.e2" /><pair ddi="false" e1="DDI-PubMed.19015329.s10.e2" e2="DDI-PubMed.19015329.s10.e3" /></sentence><sentence text=" The C(max) and AUC(0-12) of ketoconazole, dosed at 200 mg once daily, were increased by 45% (90% confidence interval = 32 to 59%) and 168% (90% confidence interval = 146 to 193%), respectively, after 2 weeks of concomitant dosing with ritonavir-boosted saquinavir (1,000 mg of saquinavir/100 mg of ritonavir given twice daily)"><entity charOffset="29-41" id="DDI-PubMed.19015329.s11.e0" text="ketoconazole" /><entity charOffset="236-245" id="DDI-PubMed.19015329.s11.e1" text="ritonavir" /><entity charOffset="254-264" id="DDI-PubMed.19015329.s11.e2" text="saquinavir" /><entity charOffset="278-288" id="DDI-PubMed.19015329.s11.e3" text="saquinavir" /><entity charOffset="299-308" id="DDI-PubMed.19015329.s11.e4" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.19015329.s11.e0" e2="DDI-PubMed.19015329.s11.e0" /><pair ddi="false" e1="DDI-PubMed.19015329.s11.e0" e2="DDI-PubMed.19015329.s11.e1" /><pair ddi="false" e1="DDI-PubMed.19015329.s11.e0" e2="DDI-PubMed.19015329.s11.e2" /><pair ddi="false" e1="DDI-PubMed.19015329.s11.e0" e2="DDI-PubMed.19015329.s11.e3" /><pair ddi="false" e1="DDI-PubMed.19015329.s11.e0" e2="DDI-PubMed.19015329.s11.e4" /><pair ddi="false" e1="DDI-PubMed.19015329.s11.e1" e2="DDI-PubMed.19015329.s11.e1" /><pair ddi="false" e1="DDI-PubMed.19015329.s11.e1" e2="DDI-PubMed.19015329.s11.e2" /><pair ddi="false" e1="DDI-PubMed.19015329.s11.e1" e2="DDI-PubMed.19015329.s11.e3" /><pair ddi="false" e1="DDI-PubMed.19015329.s11.e1" e2="DDI-PubMed.19015329.s11.e4" /><pair ddi="false" e1="DDI-PubMed.19015329.s11.e2" e2="DDI-PubMed.19015329.s11.e2" /><pair ddi="false" e1="DDI-PubMed.19015329.s11.e2" e2="DDI-PubMed.19015329.s11.e3" /><pair ddi="false" e1="DDI-PubMed.19015329.s11.e2" e2="DDI-PubMed.19015329.s11.e4" /><pair ddi="false" e1="DDI-PubMed.19015329.s11.e3" e2="DDI-PubMed.19015329.s11.e3" /><pair ddi="false" e1="DDI-PubMed.19015329.s11.e3" e2="DDI-PubMed.19015329.s11.e4" /></sentence><sentence text=" The greater exposure to ketoconazole when given in combination with saquinavir/ritonavir was not associated with unacceptable safety or tolerability"><entity charOffset="25-37" id="DDI-PubMed.19015329.s12.e0" text="ketoconazole" /><entity charOffset="69-79" id="DDI-PubMed.19015329.s12.e1" text="saquinavir" /><entity charOffset="80-89" id="DDI-PubMed.19015329.s12.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.19015329.s12.e0" e2="DDI-PubMed.19015329.s12.e0" /><pair ddi="false" e1="DDI-PubMed.19015329.s12.e0" e2="DDI-PubMed.19015329.s12.e1" /><pair ddi="false" e1="DDI-PubMed.19015329.s12.e0" e2="DDI-PubMed.19015329.s12.e2" /><pair ddi="false" e1="DDI-PubMed.19015329.s12.e1" e2="DDI-PubMed.19015329.s12.e1" /><pair ddi="false" e1="DDI-PubMed.19015329.s12.e1" e2="DDI-PubMed.19015329.s12.e2" /></sentence><sentence text=" No dose adjustment for saquinavir/ritonavir (1,000/100 mg twice daily) is required when coadministered with 200 mg of ketoconazole once daily, and high doses of ketoconazole (&gt;200 mg/day) are not recommended"><entity charOffset="24-34" id="DDI-PubMed.19015329.s13.e0" text="saquinavir" /><entity charOffset="35-44" id="DDI-PubMed.19015329.s13.e1" text="ritonavir" /><entity charOffset="119-131" id="DDI-PubMed.19015329.s13.e2" text="ketoconazole" /><entity charOffset="162-174" id="DDI-PubMed.19015329.s13.e3" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.19015329.s13.e0" e2="DDI-PubMed.19015329.s13.e0" /><pair ddi="false" e1="DDI-PubMed.19015329.s13.e0" e2="DDI-PubMed.19015329.s13.e1" /><pair ddi="false" e1="DDI-PubMed.19015329.s13.e0" e2="DDI-PubMed.19015329.s13.e2" /><pair ddi="false" e1="DDI-PubMed.19015329.s13.e0" e2="DDI-PubMed.19015329.s13.e3" /><pair ddi="false" e1="DDI-PubMed.19015329.s13.e1" e2="DDI-PubMed.19015329.s13.e1" /><pair ddi="false" e1="DDI-PubMed.19015329.s13.e1" e2="DDI-PubMed.19015329.s13.e2" /><pair ddi="false" e1="DDI-PubMed.19015329.s13.e1" e2="DDI-PubMed.19015329.s13.e3" /><pair ddi="false" e1="DDI-PubMed.19015329.s13.e2" e2="DDI-PubMed.19015329.s13.e2" /><pair ddi="false" e1="DDI-PubMed.19015329.s13.e2" e2="DDI-PubMed.19015329.s13.e3" /></sentence><sentence text="" /></document>